Hizentra

Immunoglobulin

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hizentra

Hizentra is a highly concentrated biological product that provides antibody replacement therapy. It is classified as an Immune Globulin Subcutaneous (Human) (IGSC), and its active component is Immunoglobulin G (IgG). The medicine is administered as a solution for subcutaneous injection (SCIg), which is an infusion into the tissue just beneath the skin.

Quick Facts

Property	Description
Active ingredient	Immunoglobulin G (IgG) / Human Normal Immunoglobulin
Form	20% Liquid Solution for Injection
Pharmacological Class	Immune Globulins / Passive Immunizing Agents
Common Use (General)	Antibody Replacement Therapy
Origin	Derived from large pools of human plasma

What Type of Medicine is Hizentra?

Hizentra is a specialized immune globulin preparation containing Immunoglobulin G (IgG), the main type of protective protein found in human blood. It is classified as a Passive Immunizing Agent because it directly supplies pre-formed antibodies to the body. This product is prepared specifically as a Subcutaneous Immunoglobulin (SCIg) solution, a key differentiator from related intravenous (IVIg) products. This difference in form is clinically recognized for promoting patient flexibility in managing their ongoing therapy.

What is Hizentra Made of and Where Does it Originate?

The active ingredient is Immunoglobulin G, a naturally occurring protein sourced exclusively from the large-scale pooling and fractionation of human plasma collected from thousands of healthy donors. The final, sterile, aqueous solution contains a broad spectrum of antibodies, reflecting the collective immunity of the donor population. Immunoglobulin preparations are indicated for replacement therapy in conditions associated with impaired antibody production. This means the therapy provides the necessary functional antibodies when the patient's own body is unable to produce them adequately, offering a recognized defense mechanism for the immune system.

Regulatory References

What side effects are possible with Hizentra ?

Possible Side Effects and Safety Information

The safety profile for Hizentra, an Immune Globulin Subcutaneous (Human), is formally documented by regulatory authorities, classifying adverse reactions by frequency and System-Organ Class (SOC).

Frequency Classification of Adverse Reactions

The most frequent adverse events relate to the subcutaneous administration site.

Classification	Incidence Rate (Regulatory Standard)	Common Examples
Very Common	ge 1 in 10 patients	Injection site reactions (pain, redness, swelling, induration)
Common	ge 1 in 100 to < 1 in 10 patients	Headache, Nausea, Fatigue, Myalgia (muscle pain)

Systemic side effects, such as headache and fever, are noted in regulatory documents as being more likely to appear at the start of treatment or when the infusion rate or injection site is changed.

Serious Adverse Reactions and Safety Constraints

The label includes warnings for rare but serious adverse reactions that have been documented with Immune Globulin products. These include Anaphylaxis (severe allergic reaction), Thromboembolic Events (TEEs) such as stroke and deep vein thrombosis, and conditions like Aseptic Meningitis Syndrome (AMS) and Acute Renal Dysfunction.

Population-specific safety constraints are explicitly defined. The product is contraindicated in individuals with a specific selective IgA deficiency who have documented anti-IgA antibodies, due to the high risk of severe hypersensitivity. Caution is advised for patients with cardiovascular risk factors or those who are elderly due to a potential increased risk of TEEs.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information addresses acute adverse events related to administration rather than specific symptoms resulting from an excessive dose.

Overdose Scope and Manifestations

Domain	Official Regulatory Statement
Documented Overdose Manifestations	The consequences of an overdose are not known [EMA SmPC Section 4.9].
Severe Outcomes & Systemic Effects	Shock (specifically if accidentally administered into a blood vessel); Anaphylactic reactions; Thromboembolic events (e.g., stroke, pulmonary embolism); and Aseptic Meningitis Syndrome are noted as serious potential outcomes.
Population-Specific Note	Patients with IgA deficiency with antibodies against IgA are at increased risk of severe hypersensitivity and anaphylactic reactions.

Required Emergency Actions

The regulatory guidance emphasizes immediate intervention for acute reactions and high-risk events:

Immediate discontinuation of the injection is mandated upon the suspicion of a severe systemic or anaphylactic-type reaction.
If shock occurs, standard medical treatment should be administered, and patients must be closely monitored and carefully observed.
Urgent medical help must be sought immediately. Patients are advised to go to the emergency room if experiencing severe allergic reactions such as hives, trouble breathing, or fainting, or to contact a physician immediately upon the onset of symptoms indicating a thromboembolic event, such as unexplained shortness of breath or chest pain.

This structure directs users to the explicit emergency actions and supportive measures mandated by the regulatory authorities, as no specific antidote for Hizentra is listed in the official prescribing information.

Therapeutic Uses of Hizentra

What Hizentra Treats: Main Uses and Benefits

Hizentra is an Immune Globulin Subcutaneous (Human) that is used for managing chronic conditions where immune function or nerve health is impaired, serving as antibody replacement therapy. This therapeutic profile is relevant in two primary domains.

The medicine is commonly used across conditions presenting with recurrent or episodic manifestations, specifically Primary Immunodeficiency (PI), which are often associated with recurrent and severe susceptibility to infection, and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), which can involve progressive nerve symptoms.

Protecting Against Recurrent and Severe Infections

For patients with PI, such as Common Variable Immunodeficiency (CVID), Hizentra supports the therapeutic need for antibodies. This is applied in addressing the burden of recurrent and serious bacterial infections, and supports patients during episodes of heightened discomfort. This may assist with supportive infection protection that contributes to easing the overall symptom load associated with persistent illnesses.

Stabilizing Neuromuscular Impairment in CIDP

Hizentra is commonly used as a long-term maintenance therapy for CIDP in adults. This usage is applied in addressing the symptoms of increased neurological or muscular activity such as muscle weakness and sensory loss that interfere with daily functioning. The treatment supports functional stability and helps ease distress during symptomatic periods.

Quick Fact: Relief for Chronic Symptoms
Hizentra supports general well-being and helps improve day-to-day comfort during symptomatic periods related to chronic immune or nerve conditions.

Eligibility and Restrictions for Use

Hizentra's eligibility for use is strictly defined by government regulatory agencies and centers on specific patient populations, pre-existing conditions, and age groups.

Who Must Not Use Hizentra (Contraindications)

The medicine is absolutely prohibited for use in patients with the following conditions, as stated in the prescribing information:

Hyperprolinemia Type I or II (due to the presence of the stabilizer L-proline).
A history of anaphylactic or severe systemic reaction to human normal immunoglobulin or components of Hizentra.
Immunoglobulin A (IgA) deficiency with antibodies against IgA and a history of hypersensitivity.

Approved and Restricted Populations

Population Category	Eligibility Status (Regulatory Labeling)
Primary Immunodeficiency (PI)	Adults are eligible. Pediatric patients 2 years of age and older are eligible (US FDA).
CIDP Maintenance	Adults are eligible. Use in children under 18 years has not been evaluated in clinical studies.
Patients at Risk of Thrombosis	Use requires special caution and close monitoring (e.g., advanced age, history of vascular disease, prolonged immobilization).
Pregnancy and Lactation	Use is permitted, but should only be given with caution (EMA).
Under 2 Years (PI)	Use is not officially established (US FDA).

Eligibility criteria should always be discussed with a healthcare provider based on official product labeling.

What should I know about interactions with other medicines?

Hizentra Interactions with other medicines and products

The official regulatory documents for Hizentra primarily identify a single category of interaction: the pharmacodynamic interference with specific vaccines. The medicine is a protein and does not undergo significant hepatic metabolism, which accounts for the absence of many common drug-drug interactions.

Interacting Substance Category	Officially Documented Interaction
Live Attenuated Virus Vaccines	Efficacy may be impaired by the passive transfer of Immunoglobulin G (IgG) antibodies. This applies to vaccines for measles, mumps, rubella, and varicella.
Metabolic System Inhibitors/Inducers	No documented interaction affecting plasma concentration (AUC or Cmax) is listed, as the medicine is not metabolized by the cytochrome P450 (CYP) enzyme system.
Food, Alcohol, or Supplements	No specific interaction warnings or restrictions are documented in the official prescribing information related to co-administration with meals, alcohol, or herbal products.

This pharmacodynamic effect necessitates mandatory timing-based administration rules. Vaccination with a live attenuated virus vaccine must be deferred for a period of at least three months following the use of Hizentra. For the measles vaccine, official documentation notes that this deferral period may need to be extended up to one year to ensure the intended immune response is achieved. Additionally, Hizentra must not be mixed with other medicinal products in the same infusion line.

Mechanism of Action

Hizentra is a purified, concentrated immunoglobulin G (IgG) solution, providing a broad spectrum of opsonizing and neutralizing IgG antibodies. Following subcutaneous administration, the intact IgG molecules enter the systemic circulation slowly via the lymphatic system.

The mechanism of action involves multiple interactions primarily aimed at modulating immune and inflammatory cascades. In the context of antibody replacement, the Fab domains of the IgG molecules interact with and neutralize diverse bacterial and viral antigens and toxins. This leads to opsonization of pathogens and subsequent phagocytosis by innate immune cells. The Fc domains engage with Fc receptors ( Fcgamma R) on various immunocompetent cells, including B-cells and phagocytes, which may lead to Fcgamma R antagonism and suppression of immune-mediated cellular damage. Intracellularly, this Fc-mediated signaling may modulate cytokine production and inhibit complement activation, ultimately contributing to a system-level physiological modulation of the humoral immune and inflammatory response.

Dosage and Administration Information

How to Use Hizentra — Official Administration Guidelines

Hizentra (Immune Globulin Subcutaneous [Human] Solution) is strictly administered by subcutaneous infusion (under the skin) and must never be injected into a vein (intravenously). Administration must be performed using aseptic technique (sterile practices) by a patient or caregiver who has been trained by a healthcare professional.

Administration Scope

Scope	Official Instruction
Route of Administration	Subcutaneous infusion only.
Preparation	Do not shake or freeze; visually inspect for discoloration or particles. Do not mix with other medicinal products.
Dosing Schedule	Individualized by a healthcare provider based on the patient’s clinical response and immunoglobulin G (IgG) trough levels.
Frequency	For Primary Immunodeficiency (PI), typically administered at regular intervals from daily up to every two weeks (biweekly). For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), administered weekly.

Procedural and Site Conditions

Infusions must be administered using an infusion pump (or manual push infusion in some regions) into recommended sites, which include the abdomen, thighs, upper arms, or lateral hips. Up to 8 infusion sites may be used simultaneously, with sites separated by at least 2 inches (or 5 cm).

Infusion Parameters: Official maximum limits are set for both the volume of medicine per site and the rate of infusion per site. These initial maximum limits (e.g., 15 mL volume per site and 15 mL/hr rate per site for PI) may be gradually increased based on patient tolerance, but must not exceed the prescribed limits. Patients who miss a dose should contact their healthcare provider for instruction on when to administer the next dose.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Hizentra

Evidence for Use in Primary Immunodeficiency (PI)

Research explored how the medicine was observed in patients with Primary Immunodeficiency (PI) who transition from established immunoglobulin treatments. Studies generally employed Phase 3 open-label, non-controlled clinical trial designs. The core outcome that studies examined was the annualized rate of Serious Bacterial Infections (SBIs), relevant in research describing systemic or functional imbalance. Studies monitored the maintenance of serum Immunoglobulin G (IgG) trough levels. Data show patterns related to antibody exposure comparable to that of other established immunoglobulin therapies was observed following the subcutaneous method of delivery.

Evidence for Use in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Research for its use in CIDP was evaluated in research scenarios, primarily a pivotal Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial, known as the PATH study. The study population was adult patients with CIDP who had previously demonstrated a response to intravenous immunoglobulin (IVIg) therapy. Research examined the proportion of patients who experienced a neurological relapse, which is an outcome describing episodic or acute changes in the condition. The controlled trial monitored outcomes related to daily functioning or activity level over a short-term study duration of approximately 24 weeks.

Key Evidence Gaps and Areas of Uncertainty

The research highlights several areas where data remain insufficient. A primary limitation is that for the CIDP indication, the studies focused exclusively on patients who had already demonstrated a response to IVIg. Therefore, the evidence is limited regarding patients initiating immunoglobulin therapy for the first time, and data for children (pediatric patients) with CIDP remain insufficient. Additionally, the systematic follow-up durations were limited, meaning that long-term effects are not fully established.

Frequently Asked Questions (FAQ)

Common questions about Hizentra (FAQ)

Q: Is Hizentra a permanent cure for primary immunodeficiency (PI)?

A: Official medical information describes Hizentra as a replacement therapy for Primary Immunodeficiency (PI). Replacement therapy provides missing antibodies to the body to help maintain immune function. This describes an ongoing, maintenance treatment for the condition, and not a permanent cure.

Q: Is it okay to use alcohol while using Hizentra?

A: The official prescribing information for Hizentra contains no specific warnings or restrictions documented related to the co-administration of alcohol. This indicates there is no officially documented interaction between the medicine and alcohol.

Q: Do any common over-the-counter pain relievers interact with Hizentra?

A: The official documents do not list interactions with common over-the-counter pain relievers. This is due to Hizentra being a protein that is not metabolized by the liver enzymes that process many other medicines. Consequently, no interaction affecting the medicine’s concentration in the body is documented.

Q: What is the difference between Hizentra and other similar subcutaneous IG products?

A: Official regulatory documents define Hizentra as an Immune Globulin Subcutaneous (Human) product with a specific concentration of 20%. This concentration is part of the descriptive characteristics used to distinguish its formulation from other available subcutaneous immunoglobulin solutions.

Q: How does Hizentra help people with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?

A: While the exact way the medicine works for CIDP is not fully described in official documents, it is known to involve the immunomodulatory effects of the Immunoglobulin G (IgG) antibodies. This means the IgG is thought to help regulate the body’s overall immune and inflammatory responses.

Q: Does Hizentra require any special diet or food restrictions?

A: The official prescribing information for Hizentra contains no specific warnings or restrictions documented related to co-administration with meals or specific food products.

Q: Can you travel internationally while using Hizentra?

A: The stability of the medicine is key for travel logistics. Official information states that Hizentra is stable when stored at temperatures not exceeding 25 C (77 F). Patients are advised to maintain this temperature range when handling the medicine, as required by the label information.

Q: What if I'm using an antibiotic; is that safe with Hizentra?

A: The official documentation detailing drug interactions only specifies precautions related to certain live attenuated virus vaccines. There is no specific warning listed in the prescribing information regarding the use of Hizentra with common antibiotic medicines.

Q: Does Hizentra contain any preservatives or stabilizers?

A: According to the official product information, the solution is prepared to be preservative-free. It does contain the amino acid L-proline as a stabilizer, and this component is noted in the contraindications section for patients with specific metabolic conditions.

Q: Does Hizentra contain any gluten or latex?

A: Official information confirms that the components used in the product packaging, such as the syringe or vial stopper, are not made with natural rubber latex.

Q: Can Hizentra affect mood or cause emotional changes?

A: Emotional changes or effects on mood are not listed among the most frequent (very common or common) adverse reactions in the official regulatory documents.

Q: Is it possible for a male patient using Hizentra to experience hair loss?

A: Hair loss (alopecia) is not listed among the very common or common adverse reactions in the official regulatory documents for the product.

Q: Is Hizentra used to treat autoimmune diseases other than CIDP?

A: Official labeling for the product specifies its authorized use for Primary Immunodeficiency (PI) and as a maintenance therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in adults. Use for other autoimmune diseases is not included in the official indications.

Q: Is the protection you get from Hizentra better or worse than the protection from IVIG?

A: Clinical studies examined the antibody levels (exposure) achieved with the subcutaneous delivery of Hizentra. This research showed patterns of antibody exposure that were comparable to those observed with other established intravenous immunoglobulin (IVIG) therapies.

Q: What kind of research has been done on children using Hizentra?

A: Studies have examined the use of Hizentra in pediatric patients 2 years of age and older who have Primary Immunodeficiency (PI). However, the official documents note that its use in children under 18 years for the CIDP indication has not yet been evaluated in clinical studies.

Q: How does the use of Hizentra help people with Primary Immunodeficiency (PI)?

A: Hizentra functions as antibody replacement therapy for PI patients. It supplies a broad spectrum of protective Immunoglobulin G (IgG) antibodies to the body to help the immune system fight bacterial and viral infections.

Q: What should I do if I miss my scheduled day to use Hizentra?

A: Official guidelines state that dosing is always individualized based on the patient's condition and required antibody levels. Therefore, if a dose is missed, official product guidelines advise contacting the healthcare provider for guidance on when to administer the next dose.

Q: Can other medications that suppress the immune system be used with Hizentra?

A: The official product information primarily details interactions with vaccines. Since there are many different types of immune-suppressing medicines, the labels do not provide a general statement for this category. Any question regarding co-administration of other medications should be addressed with a healthcare provider.

Q: Are there any long-term effects of using Hizentra for many years?

A: Research studies conducted for regulatory approval have included follow-up periods of limited duration. Official summaries of the research evidence indicate that long-term effects are not fully established beyond the study periods.

Q: What information is available about the long-term safety of Hizentra in CIDP patients?

A: Clinical research for the CIDP indication was conducted over a study duration of approximately 24 weeks. Because of this limited systematic follow-up time, official research summaries state that the long-term effects are not fully established.

Q: Why is it important to check for signs of kidney problems while using Hizentra?

A: Official safety warnings include the risk of Acute Renal Dysfunction (sudden kidney problems) as a rare but serious adverse reaction associated with immune globulin products. Official guidance related to the risk of renal dysfunction often includes ensuring appropriate hydration.

Q: Can patients who are pregnant or breastfeeding use Hizentra?

A: Official regulatory documents state that the medicine should only be administered with caution during pregnancy and breastfeeding. Immunoglobulin G (IgG) molecules are known to pass through the placenta and may be present in breast milk.

Q: Can Hizentra affect the results of other blood tests?

A: Because the medicine provides the body with external Immunoglobulin G (IgG) antibodies, it can cause a temporary rise in circulating antibody levels. This passive transfer of antibodies may potentially lead to a positive result on certain serological tests (blood tests that measure antibodies).

Q: Is a fever a common concern after using Hizentra?

A: Fever is listed as a potential systemic side effect. Official safety information notes that systemic reactions like fever are more likely to appear at the start of treatment or when the infusion rate is changed.

Q: Does Hizentra cause weight gain?

A: Weight gain is not listed among the very common or common adverse reactions in the official regulatory documents.

How should Hizentra be stored and disposed of?

Storage and Disposal Requirements

Hizentra must be stored at a temperature not exceeding 25 C (77 F) and must not be frozen. The product is stable for up to 30 months when stored correctly, up to the expiration date on the packaging.

Storage Restriction	Requirement
Temperature	Do not store above 25 C (77 F); Do not freeze.
Light Protection	Keep in the original outer carton to protect from light.
Stability (Opened)	Use the single-dose solution immediately after opening.
Handling	Do not shake the vial or prefilled syringe.
Child Safety	Keep the medicine out of the sight and reach of children.

Before administration, the solution must be visually inspected; do not use if it appears cloudy, contains deposits, or has been frozen. Any unused product, used administration supplies, and sharps must be discarded immediately and disposed of in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.